<DOC>
	<DOCNO>NCT01668589</DOCNO>
	<brief_summary>The main objective observational study describe medication-taking behavior patient treat denosumab postmenopausal osteoporosis ( PMO ) 12 24 month .</brief_summary>
	<brief_title>Observational Study Denosumab ( Prolia® ) Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description>The decision treat patient denosumab make independent enrolment study . No study drug administer part study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Indicated treatment osteoporosis postmenopausal woman increase risk fracture accord approve Regional Prescribing Information ( eg , EU SmPC Germany , Austria , Greece Belgium ) . Enrolled study within 4 week receive first injection Prolia® accord approve Regional Prescribing Information ( eg , EU SmPC Germany , Austria , Greece Belgium ) . Appropriate write informed consent obtain ( require per local country regulation ) . Patient currently enrol enrol within prior 6 month study involve investigational procedure , device drug . Contraindicated treatment Prolia® accord approve Regional Prescribing Information ( eg , EU SmPC Germany , Austria , Greece Belgium ) . Participation ongoing previous denosumab clinical trial . Patient kind disorder , opinion investigator , may compromise ability patient give write informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>